MPI - See MPI's CTO Thomas Jensen at TEDx Bozeman on April 9:th

2016-04-09

Company News

Hoersholm; April 9th 2016 - As previously announced, MPI's CTO, Thomas Jensen is one of the speakers at the TEDxBozeman 2016 this coming Saturday, April 9, in Bozeman, Montana, USA. The headline for his speech is "Fly Fishing & Solving Cancer. Same Same but Different!". He will be talking about the parallels he sees between fly fishing and the art of solving riddles within cancer research with the help of Drug Response Predictor - DRP(TM)

According to schedule, Thomas will go on stage at 10.56 PM Central European time, and the speech is broadcasted live here:

http://livestream.com/TEDx/Bozeman2016

The platform Drug Response Predictor - DRP(TM), which is being used by MPI and Oncology Venture, was created in 2004 at Medical Prognosis Institute, MPI, in Denmark. It is a cutting edge technology, where cell line array data from individual tumor tissue of cancer patients is translated to information relevant for treating the patient's cancer disease.
At MPI, DRP(TM) is being used for development of individually adapted cancer treatment.
With the help of DRP(TM), Oncology Venture can better the odds within development of anticancer drugs. Screening patients provides predictions of which individuals are most likely to respond positive to a certain drug candidate, and these patients can then be entered in clinical testing of the drug.

Thomas Jensen is the Chief Technology Officer for Medical Prognosis Institute and Oncology Venture. He is pioneering the bridging of good science, effective laboratory techniques, and bioinformatics to advance the biology of cancer. Amongst Thomas' accolades are his inventions of molecular biological guidelines and techniques for high-quality RNA processing.
This allows for high-resolution analysis of cancer patients' biopsies. His inventions are an important foundation of MPI's Drug Response Predictor platform - a high-resolution bioinformatics tool, that predicts the sensitivity and resistance of anticancer drugs.

What is TEDx?
For ideas worth spreading, TED has created a program called TEDx - a series of local, self-organized events that bring people together to share a TED-like experience. This weekend's event is called TEDxBozeman, where x = independently organized TED event. At TEDxBozeman, TEDTalks videos and live speakers will be combined to spark deep discussion and connection in a specific group. If you are nearby Bozeman on April 9th, come see Thomas Jensen and the other interesting speakers inspire the TEDxBozeman 2016 theme of "Confluence." If you are elsewhere, but still want to enjoy these interesting talks, you can do so live via the link above, or at the TEDx website whenever suitable. If you want to know more about this weekend's event and the other speakers, see:

http://www.tedxbozeman.com/speakers/

For further information, please contact
Peter Buhl Jensen, CEO
e-mail: pbj@medical-prognosis.com
Cell Phone: +45 21 60 89 22
http://www.medical-prognosis.com
Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark

About MPI
Medical Prognosis Institute advances personalized medicine by partnering with cancer drug developers to apply its DRP(TM) diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)
MPI's lead product, the DRP(TM) diagnostic platform, is a tool to develop tumor-derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP(TM) has been tested in 32 trials, where 26 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients had a positive effect of the treatment. The DRP(TM) platform has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anticancer drug.  Further to and in addition to this, individual patients' gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of those patients who have a high likelihood of response to the drug. The DRP(TM) platform can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US.